CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Societal CDMO Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Societal CDMO Inc
1 E. UWCHLAN AVE, SUITE 112
Phone: (770) 534-8239p:770 534-8239 EXTON, PA  19341  United States Fax: (484) 395-2471f:484 395-2471
This company ceased filing statements with the SEC on 4/18/2024.
On 4/8/2024, The Company was acquired by CoreRx, Inc., a subsidiary of QHP Capital, L.P.
This company is no longer actively traded on any major stock exchange.
This is a Subsidiary, click here for the Parent Company
Business Summary
Societal CDMO, Inc. is a bi-coastal contract development and manufacturing organization (CDMO). The Company is engaged in spanning pre-investigational new drug development to commercial manufacturing and packaging for a range of therapeutic dosage forms with a primary focus in the area of small molecules. It is a CDMO providing therapeutic development, end-to-end regulatory support, clinical and commercial manufacturing, aseptic fill/finish, lyophilization, packaging and logistics services to the global pharmaceutical market. The Company's key products include Ritalin LA, Focalin XR, Verelan PM, Verelan SR, Verapamil PM, Verapamil SR and Donnatal liquids and tablets. Its manufacturing and development capabilities include product development from formulation through clinical trial and commercial manufacturing, and specialized capabilities for solid oral dosage forms, with specialization in modified release technologies and facilities to handle potent compounds and controlled substances.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
-Yes-Yes---

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
12/31/202312/31/2023YesYes--Yes

Industries
SIC Code Description
2834 Pharmaceutical preparations

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Executive Chairman of the Board Wayne B.Weisman 67 9/20/2023 1/1/2008
President, Chief Executive Officer, Director J. DavidEnloe 59 12/15/2020 12/15/2020
Chief Financial Officer Ryan D.Lake 45 1/3/2018 6/5/2017
5 additional Officers and Directors records available in full report.

Business Names
Business Name
Development, LLC Societal CDMO San Diego, LLC
IriSys, Inc.
IriSys, LLC
7 additional Business Names available in full report.

General Information
Number of Employees: 258 (As of 12/31/2023)
Outstanding Shares: 110,550,922 (As of 4/1/2024)
Shareholders: 6
Stock Exchange: NASD
Federal Tax Id: 261523233
Fax Number: (484) 395-2471


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Tuesday, December 3, 2024